Thus, glycolysis/OXPHOS inhibition by DDM and FDR treatment may induce cancer metabolic reprogramming via a novel PI3K/AKT/mTOR/P53NF-κB/VEGF pathway in BC cells. This evidence concerns the gene AKT1 and breast cancer.